AstraZeneca has agreed to acquire Icosavax Inc., a biopharmaceutical company focused on developing vaccines, for approximately $1.1 billion. The transaction, announced Dec. 12, is expected to close in the first quarter of 2024. Seattle-based Icosavax was represented by a Latham & Watkins team led by partners Matt Bush, Cheston Larson and Daniel Rees. Counsel information for AstraZeneca was not immediately available.
Biotech & Pharmaceuticals
December 13, 2023, 10:07 AM